WANBURY LTD.

Catalyst Trusteeship Ltd, acting as Debenture Trustee, has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the release of a Non-Disposal Undertaking (NDU) on 36,83,488 equity shares of Wanbury Limited. This action, effective July 9, 2026, results in Catalyst Trusteeship Ltd holding 0% of the total share capital. The disclosure was made on July 13, 2026. The total share capital of Wanbury Limited remains unchanged at 3,49,39,398 shares.

Catalyst Trusteeship Ltd, acting as Debenture Trustee, has disclosed the release of a pledge on 85,20,330 equity shares of Wanbury Limited. These shares were held by Expert Chemicals (India) Private Limited. The release, effective July 6, 2026, reduces the encumbered shares held by Catalyst Trusteeship (on behalf of debenture holders) from 34.93% to 10.54% of Wanbury's total share capital. This action signifies a change in the shareholding structure and potentially improves the liquidity or free float of Wanbury's shares.

Catalyst Trusteeship Ltd, acting as Debenture Trustee, has disclosed the release of a pledge on 85,20,330 equity shares of Wanbury Limited. These shares were held by Expert Chemicals (India) Private Limited. The release, effective July 6, 2026, reduces the encumbered shares held by Catalyst Trusteeship Ltd to 36,83,488, representing 10.54% of the total share capital. Prior to this release, the encumbered shares constituted 24.39% of the total share capital.

Wanbury Ltd's Board of Directors, in a meeting held on June 26, 2026, approved the incorporation of a new subsidiary in India, 'Wanbury Skin Health Limited' (or similar), with an estimated capital outlay of ₹4,10,000. The board also appointed M/s. Ernst & Young LLP as the Internal Auditor and M/s. ABK & Associates as the Cost Auditor for the Financial Year 2026-2027. The meeting commenced at 3:35 p.m. and concluded at 4:15 p.m.

Wanbury Ltd's Board of Directors, in a meeting held on June 26, 2026, approved the incorporation of a new subsidiary in India with an estimated capital outlay of ₹4,10,000. The subsidiary, tentatively named Wanbury Skin Health Limited, will operate in the pharmaceutical industry. The board also appointed M/s. Ernst & Young LLP as the Internal Auditor and M/s. ABK & Associates as the Cost Auditor for the Financial Year 2026-2027. The meeting commenced at 3:35 p.m. and concluded at 4:15 p.m.

Wanbury Limited has announced the closure of its trading window for dealing in the company's securities. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain closed for designated persons, including directors, identified employees, KMPs, promoters, promoter group, and their immediate relatives, as well as connected persons. The closure commenced on July 1, 2026, and will extend until 48 hours after the declaration of the company's Unaudited Financial Results for the quarter ended June 30, 2026. The specific date for the Board Meeting to approve these results will be communicated later.

Wanbury Ltd announced the release of pledge on 1,42,03,818 equity shares (40.65% of paid-up capital) held by its Promoter Group. This release is a consequence of existing debt facilities being taken over by Axis Finance Limited & Poonawala Fincorp, replacing Investec AIF & Tata Capital Limited. Following this refinancing, only 5.49% of the Promoter Group's holding remains pledged with SBM for working capital. Additionally, the company's borrowing cost will reduce to below 10% per annum from July 1, 2026, a move expected to lower finance costs and boost profitability.

Wanbury Limited's API manufacturing facility in Tanuku, Andhra Pradesh has successfully completed a quality inspection by the Therapeutic Goods Administration (TGA) of Australia. Upon receiving the GMP certificate, the company will be able to ship an additional three APIs. This inspection reaffirms Wanbury's commitment to cGMP compliance and continuous improvement. Separately, another Wanbury API site in Patalganga received a GMP certificate from the Korean FDA (MFDS) following an inspection in April 2026.

Wanbury Limited has announced the expansion of its regulatory submissions for new Active Pharmaceutical Ingredients (APIs). The company has submitted Drug Master Files (DMFs) for Diphenhydramine HCl to Malaysia and Singapore, and plans to explore new markets for Paroxetine HCl in Korea and Latin America. Additionally, Wanbury received a zero-observation audit report from MFDS (Korea FDA) for its Patalganga facility following an inspection in April 2026, indicating strong compliance and readiness for international markets.

Wanbury Limited reported strong financial performance for FY26, with revenue from operations growing 8.5% YoY to ₹650.3 crore and PAT surging 117% YoY to ₹66.1 crore. The company's EBITDA rose 34.9% to ₹107.7 crore, supported by improved product mix, procurement efficiencies, and process optimization. Despite a temporary revenue impact in Q4 FY26 due to the West Asia crisis affecting API exports, the company maintained a strong margin profile. Operational highlights include the launch of a new Anaesthetic API, successful regulatory inspections with zero observations in Korea, and the implementation of SAP HANA S4 to drive efficiency.